InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
T+90 hit rate
33%
T+90 mean return
-11.6%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Gollob Jared, Directeur Médical. Officer active across 2 companies, notably Kymera Therapeutics, Inc.. Aggregated, 12 filings have been logged. Activity tracked since 1 November 2021. The latest transaction was filed on 8 December 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations12 total
49,307 shares@ US$5.3354.3% of flowCommon StockSEC:0001193125-25-311503:0
28,999 shares@ US$1.3117.2% of flowCommon StockSEC:0001193125-25-240430:0
800 shares@ US$1.310.5% of flowCommon StockSEC:0001193125-25-239144:0
30,000 shares0Common StockSEC:0000950170-25-031144:0
16,455 shares@ US$2.0820.1% of flowCommon StockSEC:0000950170-24-084003:0
24,375 shares0Common StockSEC:0000950170-24-025101:0
400 shares@ US$2.080.5% of flowCommon StockSEC:0000950170-24-023168:0
46,137 shares@ US$2.0856.9% of flowCommon StockSEC:0000950170-24-013482:0
18,750 shares0Common StockSEC:0000899243-23-006981:0
10,208 shares@ US$1.310.0002% mcap35.7% of flowCommon StockSEC:0000899243-22-016538:0
12,600 shares0Common StockSEC:0000899243-22-009076:0
20,000 shares@ US$1.310.0004% mcap64.3% of flowCommon StockSEC:0000899243-21-042437:0
12 of 12 declarations
About Gollob Jared
Jared Gollob is the Chief Medical Officer of Kymera Therapeutics, Inc. In this role, he is responsible for the medical direction of the company, overseeing research and development activities related to therapeutic products. His expertise in medicine and biotechnology is essential for guiding clinical initiatives and ensuring that the treatments developed meet the highest standards of safety and efficacy.
